TLP Group LLC raised its stake in shares of Qiagen NV (NASDAQ:QGEN) by 17,757.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 13,929 shares of the company’s stock after purchasing an additional 13,851 shares during the quarter. TLP Group LLC’s holdings in Qiagen were worth $450,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Verition Fund Management LLC bought a new position in Qiagen during the 1st quarter valued at about $330,000. Guggenheim Capital LLC lifted its stake in Qiagen by 42.0% during the 1st quarter. Guggenheim Capital LLC now owns 190,177 shares of the company’s stock valued at $6,145,000 after acquiring an additional 56,228 shares during the period. LPL Financial LLC bought a new position in Qiagen during the 1st quarter valued at about $316,000. A.R.T. Advisors LLC bought a new position in Qiagen during the 1st quarter valued at about $314,000. Finally, Tikvah Management LLC lifted its stake in Qiagen by 24.5% during the 1st quarter. Tikvah Management LLC now owns 442,942 shares of the company’s stock valued at $14,311,000 after acquiring an additional 87,200 shares during the period. Institutional investors and hedge funds own 62.23% of the company’s stock.
Several brokerages have recently weighed in on QGEN. Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a research note on Wednesday, June 6th. Zacks Investment Research cut shares of Qiagen from a “hold” rating to a “sell” rating in a research note on Monday, April 9th. DZ Bank reiterated a “neutral” rating on shares of Qiagen in a research note on Thursday, April 5th. TheStreet upgraded shares of Qiagen from a “c+” rating to a “b” rating in a research note on Friday, May 25th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Qiagen in a research note on Thursday, May 3rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $35.55.
Qiagen (NASDAQ:QGEN) last released its earnings results on Wednesday, May 2nd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The company had revenue of $343.60 million during the quarter, compared to analyst estimates of $339.30 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.22 EPS. sell-side analysts predict that Qiagen NV will post 1.34 earnings per share for the current year.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.